


# PRODUCT INFORMATION



## LOR253

Item No. 36773

**CAS Registry No.:** 916151-99-0  
**Formal Name:** 2-(5-fluoro-2-methyl-1H-indol-3-yl)-1H-imidazo[4,5-f][1,10]phenanthroline  
**Synonym:** APTO-253  
**MF:** C<sub>22</sub>H<sub>14</sub>FN<sub>5</sub>  
**FW:** 367.4  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 230, 262, 284 nm  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

LOR253 is supplied as a solid. A stock solution may be made by dissolving the LOR253 in the solvent of choice, which should be purged with an inert gas. LOR253 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of LOR253 in these solvents is approximately 2 mg/ml.

### Description

LOR253 is an activator of the transcription factor Kruppel-like factor 4 (KLF4).<sup>1</sup> It increases levels of KLF4 and induces apoptosis in HCC1187, HCC38, and MDA-MB-468 cancer cells when used at concentrations of 5 and 10 μM. It is cytotoxic in a panel of 16 acute myeloid leukemia (AML) and lymphoma cell lines (IC<sub>50</sub>s = 0.057-1.75 μM) and induces cell cycle arrest at the G<sub>0</sub>/G<sub>1</sub> phase in MV4-11, KG-1, and EoL-1 cells.<sup>2</sup> LOR253 (1 mg/kg) accelerates wound healing, as well as increases plasma levels of KLF4 and wound site myeloid-derived suppressor cell (MDSC) accumulation, in an *ob/ob* mouse model of diabetic wound healing.<sup>3</sup>

### References

1. Nakajima, W., Miyazaki, K., Asano, Y., *et al.* Krüppel-like factor 4 and its activator APTO-253 induce NOXA-mediated, p53-independent apoptosis in triple-negative breast cancer cells. *Genes (Basel)* **12(4)**, 539 (2021).
2. Local, A., Zhang, H., Benbatoul, K.D., *et al.* APTO-253 stabilizes G-quadruplex DNA, inhibits MYC expression, and induces DNA damage in acute myeloid leukemia cells. *Mol. Cancer Ther.* **17(6)**, 1177-1186 (2018).
3. Yang, X., Mathis, B.J., Huang, Y., *et al.* KLF4 promotes diabetic chronic wound healing by suppressing Th17 cell differentiation in an MDSC-dependent manner. *J. Diabetes Res.* 7945117 (2021).

**WARNING**  
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

**SAFETY DATA**  
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

**WARRANTY AND LIMITATION OF REMEDY**  
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/21/2022

### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM